Key HighlightsVirTra (NASDAQ:VTSI) traded at USD 3.58 in intraday trading on November 13, 2026, up 36.64%, on about 3.4 million shares against a three-month average of only about 68,143.Third quarterRevenuerose 42% to USD 7.6 million andNet Incomewas USD 2.2 million, or USD 0.19 per …
The lead program, JADE101, is an anti-APRIL antibody for IgA nephropathy. Interim Phase 1 results showed mean IgA reductions of about 70% after a single 700 mg dose, with good tolerability across all doses. Dosing has begun in the Phase 2 JUNIPER trial, with …
Second quarter net revenue of BRL 4.1 billion rose 67% year over year. Net interest income was BRL 2.0 billion, up 65%, and gross profit was BRL 1.2 billion, up 48%. Non-credit revenue reached BRL 1.9 billion, up 57%, while revenue from secured and …
In the second quarter the net loss was USD 11.3 million, or 0.07 per share, versus 0.08 per share in the first quarter and 0.21 a year earlier.Research and Developmentexpense was USD 5.8 million, while a non-cashWarrantfair-value gain of USD 5.5 million and other …
The second quarter net loss was USD 430.4 million, compared with USD 2.6 million a year earlier, and the loss per share was 26.16 versus 2.41. The result was dominated by a USD 400.4 million non-cash fair value loss on convertible notes rather than …
Second quarter revenue of RMB 6.29 billion included membership services of RMB 4.01 billion, online advertising of RMB 1.25 billion, content distribution of RMB 681.5 million and other revenues of RMB 344.9 million, down 58% after a change in aBusinesscooperation arrangement. Selling, general and …
Second quarter revenue was USD 82.6 million, with chatting services contributing USD 47.4 million and games USD 34.2 million. Net income was USD 29.3 million, a 35.5% margin, versus USD 36.5 million a year earlier, and non-GAAP net income was USD 34.4 million, a …
The Rationale: Last Reported Quarter and Management Outlook for Polestar Automotive Holding UK PLC (NASDAQ:PSNY)
In the second quarter of 2026 the company posted an operating loss of USD 38.6 million, compared with USD 12.6 million a year earlier, as total operating expenses rose to USD 41.9 million from USD 13.0 million.Research and Developmentwas USD 14.2 million, sales andMarketingUSD …
Key HighlightsBioCryst Pharmaceuticals (NASDAQ:BCRX) appears on the aggressive small cap screen with a one-year EPS change of 3,194.70% and aMarket Valueof about USD 1.95 billion, at USD 7.57 in the November 13 snapshot.Third quarter 2026Revenuerose 13% to USD 180.3 million, andGAAPNet Incomenearly tripled to …